EMA Authorised: Imnovid (previously Pomalidomide Celgene) (Pomalidomide) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The EMA authorised Imnovid (pomalidomide) for use in multiple myeloma, with Bristol-Myers Squibb Pharma EEIG as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Imnovid (Pomalidomide)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 21/08/2025